Nichola Webster

838 total citations · 1 hit paper
9 papers, 296 citations indexed

About

Nichola Webster is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Nichola Webster has authored 9 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 6 papers in Pathology and Forensic Medicine and 2 papers in Immunology. Recurrent topics in Nichola Webster's work include Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (6 papers) and Genetic factors in colorectal cancer (2 papers). Nichola Webster is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (6 papers) and Genetic factors in colorectal cancer (2 papers). Nichola Webster collaborates with scholars based in United Kingdom. Nichola Webster's co-authors include Peter J. Campbell, Eve Roman, Philip Beer, Daniel J. Hodson, Camilo Ruiz, Susanna L. Cooke, Daniel Painter, Alexandra Smith, Sharon Barrans and Paul Glover and has published in prestigious journals such as Blood, Blood Advances and Hematological Oncology.

In The Last Decade

Nichola Webster

6 papers receiving 295 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

2020 260 citations Stuart Lacy, Sharon Barrans et al. Blood profile →

Peers

Nichola Webster

PFM

ONCOL

GENET

IMMUN

MB

Stefano Rosati Netherlands

Bishan Ye United States

Pablo Mozas Spain

Nele Fourneau United States

Chiyoko Ueda Japan

Felicia Gomez United States

Claudia Mannu Italy

Simon Rule United Kingdom

Kathryn Turner United Kingdom

Kirsty Wienand United States

Stefano Rosati Netherlands

Nichola Webster

229 ×0.9

PFM

174 ×1.1

ONCOL

120 ×0.9

GENET

35 ×0.6

IMMUN

80 ×1.4

MB

Citations per year, relative to Nichola Webster Nichola Webster (= 1×) peers Stefano Rosati

Countries citing papers authored by Nichola Webster

Since Specialization

Citations

This map shows the geographic impact of Nichola Webster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nichola Webster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nichola Webster more than expected).

Fields of papers citing papers by Nichola Webster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nichola Webster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nichola Webster. The network helps show where Nichola Webster may publish in the future.

Co-authorship network of co-authors of Nichola Webster

This figure shows the co-authorship network connecting the top 25 collaborators of Nichola Webster. A scholar is included among the top collaborators of Nichola Webster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nichola Webster. Nichola Webster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Rawstron, Andy C., David Cairns, Nichola Webster, et al.. (2025). Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.. Blood. 146(Supplement 1). 794–794.

2.

Dalal, Surita, Darren Newton, Nichola Webster, et al.. (2025). Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patients. Blood. 146(Supplement 1). 796–796.

3.

Rawstron, Andy C., Nichola Webster, Surita Dalal, et al.. (2023). Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. Blood. 142(Supplement 1). 632–632. 1 indexed citations

4.

Crouch, Simon, Daniel Painter, Sharon Barrans, et al.. (2022). Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network. Blood Advances. 6(21). 5716–5731. 17 indexed citations

5.

Crouch, Simon, Daniel Painter, Sharon Barrans, et al.. (2021). MOLECULAR SUBCLUSTERS OF FOLLICULAR LYMPHOMA: A REPORT FROM THE UK'S HAEMATOLOGICAL MALIGNANCY RESEARCH NETWORK. Hematological Oncology. 39(S2).

6.

Lacy, Stuart, Sharon Barrans, Philip Beer, et al.. (2020). Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 135(20). 1759–1771. 260 indexed citations breakdown →

7.

Hillmen, Peter, Rebecca H. Boucher, Nichola Webster, et al.. (2020). Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. Blood. 136(Supplement 1). 17–18. 13 indexed citations

8.

Rawstron, Andy C., Peter Hillmen, Nichola Webster, et al.. (2020). Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure. Blood. 136(Supplement 1). 27–28. 2 indexed citations

9.

Rawstron, Andy C., Kristian Brock, Nichola Webster, et al.. (2018). Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure. Blood. 132(Supplement 1). 181–181. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact